# Ovarian Cancer Immunotherapy and Personalized Medicine

Review · Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J

- Archive id: doi:10.3390/ijms22126532
- Published: 2021-06-18
- Venue: International journal of molecular sciences
- DOI: https://doi.org/10.3390/ijms22126532
- PMID: 34207103
- PMCID: PMC8234871
- Citations: 307
- Source URL: https://doi.org/10.3390/ijms22126532
- PDF: https://europepmc.org/articles/PMC8234871/pdf
- Provenance: europepmc

## Abstract

Ovarian cancer response to immunotherapy is limited; however, the evaluation of sensitive/resistant target treatment subpopulations based on stratification by tumor biomarkers may improve the predictiveness of response to immunotherapy. These markers include tumor mutation burden, PD-L1, tumor-infiltrating lymphocytes, homologous recombination deficiency, and neoantigen intratumoral heterogeneity. Future directions in the treatment of ovarian cancer include the utilization of these biomarkers to select ideal candidates. This paper reviews the role of immunotherapy in ovarian cancer as well as novel therapeutics and study designs involving tumor biomarkers that increase the likelihood of success with immunotherapy in ovarian cancer.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [Cancer Immunotherapy](https://space-kitty.com/topics/cancer-immunotherapy)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.